June 20, 2025

Hormone Levels May Guard Against MetS

A large national study of U.S. women ages 12 to 49 found that higher levels of testosterone and sex hormone–binding globulin were linked to lower odds of metabolic syndrome, with differences observed across racial and ethnic groups.

Conexiant

June 19, 2025

GLP-1 Use Associated with Less Pain, Fatigue

At the EULAR 2025 Congress, researchers reported that GLP-1 receptor agonists were linked to reduced opioid use, pain, and fatigue in fibromyalgia patients based on a large real-world analysis.

Conexiant

June 19, 2025

Is More Fiber the Heart’s Ally?

A long-term U.S. study found that greater adherence to a plant-based cholesterol-lowering diet was linked to lower cardiovascular, coronary heart disease, and all-cause mortality.

Conexiant

June 18, 2025

Weight Loss Showdown: Pills or Scalpel?

A large analysis presented at the ASMBS Annual Meeting found bariatric surgery led to greater long-term weight loss than GLP-1 medications semaglutide and tirzepatide over three years.

Conexiant

June 17, 2025

Global Study Maps Sex Differences in Care

A global study found sex differences in risk factors, care access, and mortality for hypertension, diabetes, and HIV, using comprehensive international datasets.

Conexiant

June 17, 2025

Does Stopping Obesity Treatment Early Undermine Success?

A large real-world study found that early discontinuation of semaglutide or tirzepatide in patients with obesity led to significantly smaller reductions in body weight and HbA1c compared to patients who continued treatment.

Conexiant

June 16, 2025

Can One Drug Decode Obesity’s Roots?

A new treatment for rare, extreme hunger offers life-changing relief and uncovers clues to obesity’s tangled biology—reshaping how we understand and treat the condition.

KFF Health News

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Obicetrapib-Ezetimibe Combo Cuts LDL Nearly 50%

A phase 3 trial of an oral fixed-dose combination of obicetrapib and ezetimibe showed a nearly 50% reduction in LDL cholesterol levels in patients at high risk for heart disease, without added safety concerns.

Conexiant